The ITGB1BP1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ITGB1BP1 gene in the human NCI-H1975 lung adenocarcinoma epithelial cell line. This polyclonal population provides a loss-of-function model for studying ITGB1BP1 (integrin beta1 binding protein 1, also known as ICAP1) without the limitations of clonal selection. The use of polyclonal knockout cells ensures a heterogeneous yet targeted gene disruption, enabling robust analysis of ITGB1BP1-dependent cellular processes while minimizing clonal artifacts. This model is suitable for researchers investigating integrin-mediated signaling and cerebral cavernous malformation (CCM) pathways.
The parental NCI-H1975 cell line is a widely used in vitro model of human lung adenocarcinoma, derived from a non-small cell lung carcinoma patient. These epithelial cells harbor EGFR L858R and T790M mutations, conferring sensitivity to EGFR tyrosine kinase inhibitors, along with oncogenic KRAS signaling. The cell line displays typical epithelial morphology and is extensively characterized for studies on drug resistance, migration, and metastasis. Its clinically relevant mutations make NCI-H1975 ideal for evaluating ITGB1BP1 function in a context where integrin and oncogenic kinase pathways intersect.
ITGB1BP1 encodes the scaffolding protein ICAP1, which directly binds the cytoplasmic tail of integrin beta1 and negatively regulates cell adhesion and migration. ICAP1 competes with talin for integrin binding, modulating focal adhesion dynamics. Upstream, integrin activation by ECM ligands and TGF-beta signaling recruit ICAP1 to adhesion sites. ICAP1 interacts with KRIT1 (CCM1) to suppress RhoA GTPase and downregulate FAK phosphorylation, forming a core complex with CCM2 and PDCD10 in the cerebral cavernous malformation pathway. Through this network, ITGB1BP1 controls cytoskeletal reorganization and endothelial barrier integrity. Consequently, ITGB1BP1 disruption alters integrin beta1 signaling, FAK activity, and RhoA-mediated actin remodeling.
In the NCI-H1975 background, ITGB1BP1 knockout allows dissection of integrin beta1 signaling amid oncogenic EGFR and KRAS activation. This cell line’s moderate metastatic potential and integrin-dependent adhesion make it suitable to study how loss of ICAP1-mediated regulation affects motility, invasion, and ECM interaction. Cross-talk between integrin and growth factor receptor signaling can be interrogated to assess if ITGB1BP1 modulates EGFR inhibitor sensitivity or focal adhesion dynamics. Moreover, this model supports investigation of ICAP1’s potential tumor-suppressive or -promoting roles in NSCLC, where integrin beta1 dysregulation is implicated in progression.
This ITGB1BP1 knockout model is well suited for diverse functional assays. Cell adhesion, transwell migration, and Matrigel invasion assays directly evaluate integrin-mediated adhesive and migratory phenotypes. Western blotting for FAK, RhoA, and downstream targets quantifies signaling alterations, while co-immunoprecipitation verifies disrupted ICAP1-integrin beta1 complexes. Immunofluorescence staining for focal adhesion markers (e.g., paxillin, vinculin) visualizes structural changes. GTPase activity assays probe RhoA activation relevant to CCM signaling. The polyclonal population is also applicable for drug sensitivity screens, siRNA synergies, and rescue experiments. Its heterogeneous knockout background provides a robust system for studying gene function without clonal bias. For further information, contact Ascent Research.
